Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
-
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
-
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
-
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
-
Immuneering to Present at the Jefferies Global Healthcare Conference
-
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
-
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
-
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
-
Immuneering Corporation Announces Grant of Inducement Award
-
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates